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Abstract
Background: Bone mineral density (BMD) loss commonly occurs after hematopoietic cell transplantation (HCT).
Hypothesizing that genetic variants may influence post-HCT BMD loss, we conducted a prospective study to examine
the associations of single nucleotide polymorphisms (SNP) in bone metabolism pathways and acute BMD loss after HCT.
Methods and Findings: We genotyped 122 SNPs in 45 genes in bone metabolism pathways among 121 autologous and
allogeneic HCT patients. BMD changes from pre-HCT to day +100 post-HCT were analyzed in relation to these SNPs in linear
regression models. After controlling for clinical risk factors, we identified 16 SNPs associated with spinal or femoral BMD loss
following HCT, three of which have been previously implicated in genome-wide association studies of bone phenotypes,
including rs2075555 in COL1A1, rs9594738 in RANKL, and rs4870044 in ESR1. When multiple SNPs were considered
simultaneously, they explained 5–35% of the variance in post-HCT BMD loss. There was a significant trend between the
number of risk alleles and the magnitude of BMD loss, with patients carrying the most risk alleles having the greatest loss.
Conclusion: Our data provide the first evidence that common genetic variants play an important role in BMD loss among
HCT patients similar to age-related BMD loss in the general population. This infers that the mechanism for post-HCT bone
loss is a normal aging process that is accelerated during HCT. A limitation of our study comes from its small patient
population; hence future larger studies are warranted to validate our findings.
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Introduction
After the second decade of life, bone mineral density (BMD)
gradually declines as a result of normal aging [1]. This process is
accelerated in patients undergoing hematopoietic cell transplan-
tation (HCT) [2,3]. Rapid bone loss weakens bone strength and
may permanently impair bone remodeling capability [4,5], putting
HCT survivors at high risk of premature fracture. We previously
demonstrated that BMD loss within 4 months after HCT is
equivalent to 7 to 17 years of normal bone aging [6]. Moreover,
this loss occurs following autologous and allogeneic HCT with a
similar incidence and severity.
In the general population, the inherited genetic background
accounts for a large proportion of phenotypic variation in BMD
loss and fracture risk [7,8]. In numerous candidate gene
association studies, a variety of genetic variants, mostly in the
form of single nucleotide polymorphisms (SNP), have been
associated with regulation of BMD and risk of fracture [9], with
less than a handful of them confirmed in a recent large-scale meta-
analysis performed by the Genetic Factors for Osteoporosis
(GEFOS) Consortium [10]. A genome-wide association (GWA)
approach has also been used to search for loci associated with
various bone phenotypes, which identified a number of novel
SNPs [11,12,13,14,15]. These genetic markers may have clinical
significance in predicting risk of BMD loss and/or osteoporosis.
Moreover, some may also be predictive for response to therapies
targeting related molecules or pathways, such as a human
monoclonal antibody against receptor activator of nuclear factor
kB ligand (RANKL) (denosumab), which was recently approved
by the FDA for postmenopausal women at risk for fracture [16].
Among HCT recipients, rapid BMD loss may be due to an
accelerated bone aging process after exposure to high doses of
corticosteroids, chemotherapy and/or total body irradiation.
Indeed, we have previously demonstrated that bone loss occurs
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HCT patients [6]. Therefore, predisposing genetic variants for
low BMD and osteoporosis in the general population may also
predispose carriers to risk of severe post-HCT BMD loss.
Recently, McClune and colleagues proposed comprehensive
guidelines for the screening, prevention and treatment of
osteoporosis after HCT. They recommend dual-energy X-ray
absorptiometry (DXA) scans for all adult patients 1 year post-
HCT or earlier for patients at high risk of bone loss [17].
Bisphosphonates are effective in reducing or reversing HCT-
related bone loss in several small randomized studies; however,
they rarely resolve bone loss to pre-HCT levels and have a
significant side-effect, osteonecrosis of the jaw. We hypothesized
that genetic variants are associated with BMD loss in HCT
patients, and sought to identify a panel of genetic biomarkers that
can be incorporated into the above guidelines to personalize
prevention and treatment strategy.
Methods
Ethics statement: Stem cell transplant patients at the Blood and
Marrow Transplantation Program included in this study are part
of an institution-level Data Bank and Biorepository (DBBR) at
Roswell Park Cancer Institute (RPCI). All participants have
provided written consent for their data and biospecimens to be
used for research purposes. This study has been reviewed and
approved by RPCI Institutional Review Board.
Patients, BMD measurement, and DNA specimens
A detailed description of the patient population has been
published previously [6]. Briefly, between 1/2006 and 1/2009,
206 consecutive adult ($18 years) patients underwent their first
HCT in the Blood and Marrow Transplantation Program at
Roswell Park Cancer Institute (RPCI). As part of routine clinical
care, the average BMD at lumbar spine (L2–L4) and dual femurs
were measured by DXA scans at baseline (pre-HCT) and day
+100 post-HCT. The median time for 197 patients (96%) who had
a baseline DXA scan was 20 days before HCT, and 98 days for
146 patients (74%) who had a second DXA scan after HCT.
Reasons for not obtaining a follow-up DXA scan were unstable
medical status (n=14), or disease relapse/early death (n=37).
Before HCT, patients were invited to participate in the DataBank
and BioRepository (DBBR), a comprehensive data and biospeci-
men core facility at RPCI [18]. Upon their consent to the DBBR,
blood samples were drawn and genomic DNA was extracted and
stored for multidisplinary research. For this study, 121 patients
including 67 autologous and 54 allogeneic HCT patients,
consented to the DBBR and had adequate DNA available for
genotyping.
Candidate gene and SNP selection and genotyping
Candidate genes from bone metabolism pathways were selected
based on the following criteria: (1) genes that have been well
studied and established in association with osteoporosis or other
bone phenotypes in the general population; (2) key genes in bone
metabolism pathways, including osteoblast or osteoclast differen-
tiation, proliferation and activation; calcitronic hormone metab-
olism and activation; and bone matrix formation and regulation.
As listed in Table S1, a total of 45 candidate genes were clustered
into 4 groups based on underlying biological function, including
(1) RANKL-RANK-OPG central signaling axis and regulating
cytokines, (2) bone matrix proteins and regulating factors, (3)
vitamin D receptor and metabolizing enzymes, and (4) steroid
hormones and receptors.
SNPs for each candidate gene were selected based on the
following criteria: (1) minor allele frequency (MAF) $0.10 in the
population of European ancestry; (2) SNPs that have been well
studied and established in association with osteoporosis or other
bone traits in the general population, including those identified in
recent GWA studies and the large prospective study Genetic
Factors for Osteoporosis (GEFOS) Consortium [10]; (3) coding
SNPs and SNPs in the 39 or 59 untranslated region (UTR); and (4)
tagSNPs selected by the Tagger program [19] from the HapMap
Project data [20], if no functional SNPs or well studied SNPs were
available. In all, 158 SNPs were initially selected from the 45
candidate genes. To remove redundant SNPs due to high linkage
disequilibrium (LD), pair-wise r
2 was computed for SNPs in each
gene and in genes clustered on the same chromosome by PLINK
[21]; SNP_tools [22] was used for necessary data formatting. For
SNP pairs in high LD (r
2$0.90), one SNP was randomly selected
from each pair for further consideration. As a result, a total of 122
SNPs were included in the final analysis (see Table S1).
Genotyping of DNA extracted from peripheral blood was
performed in the Genomics Shared Resource at RPCI utilizing the
MassARRAYH technology and iPLEX Gold assay (Sequenom).
Nine percent duplicate samples and in-house Coriell trio samples
were included within plates and across plates for genotyping
quality assurance. The average qualified call rate was 98.1% for
each SNP and 98.3% for each DNA sample. There was no
discordance among duplicate pairs, and no SNPs violated
Mendelian inheritance or Hardy-Weinberg equilibrium.
Statistical analysis
All analyses were performed stratified by autologous and
allogeneic HCTs since these two treatments, and the character-
istics of the patients given these two treatments, are significantly
different. Change in BMD was standardized to 100 days (BMD
change divided by the number of days between the two DXA
scans then times 100) and used as a continuous variable; thus, a
negative value indicates BMD loss and a positive value indicates
BMD gain. We used linear regression models to analyze the
association of clinical factors and genetic variants with four
separate outcomes: BMD changes at the spine and at the femur in
autologous and allogeneic HCT patients. Assuming an additive
genetic model, 54 patients in the small allogeneic HCT group and
two-sided p-value of 0.05, we had 80% power to detect a
minimum BMD change of 0.023–0.040 g/cm
2 for a SNP with a
minor allele frequency between 0.10–0.50. In the autologous HCT
group which had a larger sample size of 67, we had 80% power to
detect effect sizes ,0.023 g/cm
2.
Single SNP analysis. SNPs associated with HCT-induced
BMD change were identified as follows. First, each SNP was tested
individually in a simple linear regression model without controlling
for covariates; SNPs with p,0.10 were then added to regression
models previously built with clinical factors for each of the four
outcomes, including the cumulative dose of corticosteroids (in
prednisone equivalents) between the two DXA scans for BMD loss
in allogeneic HCT patients [6]. We measured the proportion of
variance explained by all the covariates retained in a model, R
2,
and determined, DR
2, an estimate of the proportion of variance
that can be explained by the SNP(s) added to the base model, with
adjustment for the number of covariates in the model. A SNP with
a DR
2 of 5% or higher was deemed significant. Effect size (i.e.,
absolute BMD change) per copy of the variant allele and 95%
confidence intervals (CI) were calculated for each significant SNP,
with and without adjustment for clinical risk factors. The rate of
annualized BMD change between pre- and post-HCT DXA scans
was compared and plotted by the genotypes of each significant
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the SNP and CNV Annotation Database (SCAN) [23] was
surveyed to explore whether it is a potential expression
quantitative trait loci (eQTL) that has been associated with
altered gene expression.
Multiple-SNP analysis. We examined the combined effects
of multiple variants using backward elimination. SNPs with a
p#0.05 were retained in the final models. Adjusted R
2 was
calculated for the complete models with both clinical and genetic
factors and compared to the base models with only clinical factors,
to determine the overall contribution of genetic factors. For SNPs
retained in the model, the number of risk alleles was summed for
each patient, and the annualized rate of BMD change was
compared across patients by number of risk alleles. Although we
measured change in BMD between a set interval of approximately
100 days, we presented annualized BMD loss rates for
comparisons to the general population. Prior reports of BMD
loss post-HCT demonstrated that reversal of BMD loss takes
several years after HCT [3]. Multiple-SNP analysis was not
performed for spinal BMD loss after allogeneic HCT because only
Table 1. Characteristics of HCT patients with BMD measurement and genomic DNA samples.
Characteristics Autologous HCT (n=67) Allogeneic HCT (n=54)
Age at HCT in years 57 (25–74) 47 (18–71)
Spine BMD at baseline, median (range), g/cm
2 1.23 (0.71–1.65) 1.20 (0.86–1.83)
Femur BMD at baseline, median (range), g/cm
2 1.04 (0.60–1.41) 1.09 (0.71–1.45)
Gender
Male 42 (63%) 30 (56%)
Female 25 (37%) 24 (44%)
Race
White 59 (88%) 52 (96%)
Other 8 (12%) 2 (4%)
Diagnosis
Acute leukemia 3 (4%) 34 (63%)
Lymphoma 37 (55%) 9 (17%)
Myeloma 27 (40%) 0
Other 0 11 (20%)
Disease status at HCT
CR1/untreated MDS 29 (43%) 38 (70%)
CR2+/PIF/Relapse 38 (57%) 16 (30%)
Graft source
Bone marrow 6 PBSC 6 (9%) 8 (15%)
PBSC 61 (91%) 46 (85%)
Conditioning regimen
Myeloblative 67 (100%) 19 (35%)
Reduced Intensity 0 32 (59%)
Non-myeloblative 0 3 (6%)
GvHD prophylaxis regimen
CsMt/FKMt - 19 (35%)
FK/FKMMF - 15 (28%)
FKMtMMF 20 (37%)
Donor relation
Unrelated - 36 (67%)
Related - 18 (33%)
HLA match
Matched - 45 (83%)
Mismatched - 9 (17%)
Acute GvHD
Grade 0–I - 26 (48%)
Grade II–IV - 28 (52%)
Abbreviations: BMD, bone mineral density; CR, complete remission; Cs, cyclosporine; FK, tacrolimus; GvHD, graft-versus-host disease; HCT, hematopoietic cell
transplantation; HLA, human leukocyte antigen; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; Mt, methotrexate; PIF, primary induction failure; PBSC,
peripheral blood stem cell.
doi:10.1371/journal.pone.0025940.t001
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analyses were two-tailed and were performed with SAS 9.2 (SAS
Institute, Cary, NC).
Results
Individual SNP analysis
Table 1 summarizes the demographic and clinical characteris-
tics of the study population separately by auto- and allo-HCT
groups, which were statistically similar to the overall patient
population described in our prior report [6]. Unadjusted p-values
for associations between individual SNPs and BMD change
between pre- and post-HCT are shown in Figure S1. After
controlling for clinical risk factors, at least one SNP remained
significant for each of the four outcomes, with a total of 16
significant SNPs for all four outcomes. SNP rs2075555 in the
COL1A1 gene remained significant after Bonferroni correction for
multiple comparisons (p=0.037).
Table 2 summarizes the unadjusted and adjusted BMD change
associated with each of the 16 SNPs significant in individual SNP
tests. Annualized rate of BMD change by genotype are shown in
Figure 1. There was a significant dose-response trend between rate
of BMD loss and number of risk alleles at the spine and the femur
in autologous HCT and at the femur in allogeneic HCT. The
functions of these genes, SNPs and published literature are
summarized in Table S2. Among these, three SNPs, including
rs2075555 in COL1A1 gene [11,24], rs9594738 in RANKL gene
[13] and rs4870044 in ESR1 gene [13], were significantly
associated with bone phenotypes in GWA studies of the general
population. Moreover, rs2075555 and rs9594738 were associated
with altered gene expression in the SCAN (p,0.0001). Another 9
significant SNPs in our analysis were previously linked to bone
phenotypes in candidate gene association studies, including rs4588
in GC, rs6256 in PTH, rs419598 in IL1RN, rs1801131 in MTHFR,
rs1800896 in IL10, and rs1061624 in TNFRSF1B, rs1042358 in
ALOX12, rs759330 in BGLAP, and rs2235579 in CLCN7. Four of
these SNPs (rs759330, rs2235579, rs1800896 and rs1061624) were
also associated with altered gene expression in the SCAN. The
other 4 SNPs, including rs3787557 and rs2296241 in CYP24A1,
rs25645 in CSF3, and rs1321080 in RUNX2, were selected as
tagSNPs or SNPs in functional genomic regions, with no known
associations with bone phenotypes. Two of these SNPs (rs2296241
and rs25645) were associated with altered gene expression in the
SCAN.
Multiple-SNP analysis
The multiple-SNP models are shown in Table 3. For the spinal
BMD change after autologous HCT, three SNPs (rs759330 in
Table 2. Change in bone mineral density per copy of the variant allele for individual SNPs which were significant in the
multivariable models including clinical risk factors
1.
Gene SNP
Unadjusted BMD change
per copy of variant
allele (95% CI), g/cm
2
Unadjusted
P-value
Adjusted BMD change
per copy of variant
allele (95% CI), g/cm
2
Adjusted
P-value
Spinal bone mineral density change after autologous hematopoietic cell transplantation
BGLAP rs759330 20.024 (20.04520.002) 0.03 20.026 (20.04720.006) 0.01
CLCN7 rs2235579 0.016 (20.001–0.034) 0.07 0.019 (0.002–0.036) 0.03
GC rs4588 20.031 (20.05120.011) 0.003 20.024 (20.04520.003) 0.02
CYP24A1 rs3787557 20.055 (20.09520.016) 0.007 20.049 (20.08720.010) 0.01
PTH rs6256 0.036 (0.004–0.067) 0.03 0.032 (0.002–0.063) 0.04
Femoral bone mineral density change after autologous hematopoietic cell transplantation
IL1RN rs419598 20.014 (20.02620.003) 0.01 20.014 (20.02520.004) 0.009
CSF3 rs25645 0.011 (0.002–0.021) 0.02 0.011 (0.002–0.020) 0.02
MTHFR rs1801131 0.022 (0.009–0.036) 0.001 0.020 (0.08–0.033) 0.008
ALOX12 rs1042357 20.016 (20.02720.005) 0.004 20.014 (20.02520.003) 0.01
CYP24A1 rs2296241 0.014 (0.004–0.024) 0.01 0.014 (0.004–0.024) 0.01
ESR1 rs4870044 20.011 (20.02320.000) 0.06 20.015 (20.02520.004) 0.008
Spinal bone mineral density change after allogeneic hematopoietic cell transplantation
RANKL rs9594738 20.029 (20.05220.007) 0.01 20.020 (20.03920.001) 0.04
Femoral bone mineral density change after allogeneic hematopoietic cell transplantation
RANKL rs9594738 20.022 (20.04220.003) 0.02 20.018 (20.03620.001) 0.05
IL10 rs1800896 20.016 (20.03520.002) 0.08 20.022 (20.03920.005) 0.01
TNFRSF1B rs1061624 20.023 (20.04120.004) 0.02 20.021 (20.03920.003) 0.02
COL1A1 rs2075555 20.052 (20.08020.024) 0.0003 20.050 (20.07720.023) 0.0006
RUNX2 rs1321080 20.028 (20.05120.006) 0.02 20.024 (20.04720.002) 0.03
Footnote:
1The clinical risk factors included in the multivariable models are: (1) Spinal BMD change after autologous HCT: spinal BMD at baseline and diagnosis (lymphoma vs
others); (2) Femoral BMD change after autologous HCT: age at HCT and diagnosis (lymphoma vs others); (3) Spinal BMD change after allogeneic HCT: spinal BMD at
baseline, weight at baseline, and steroid dose; (4) Femoral BMD change after allogeneic HCT: femoral BMD at baseline, weight at baseline, and steroid dose. Please refer
to Table S2 for description of functions of these genes and SNPs. Abbreviation: BMD, bone mineral density; CI, confidence interval; HCT, hematopoietic cell
transplantation; SNP, single nucleotide polymorphism.
doi:10.1371/journal.pone.0025940.t002
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the final model and explained 16% of the variance in BMD loss, in
addition to the 10% determined by the clinical risk factors.
Similarly, SNPs retained in the final models explained an
additional 35%, 5% and 29% of the variance in femoral BMD
loss after autologous HCT, spinal BMD loss after allogeneic HCT,
and femoral BMD loss after allogeneic HCT, respectively.
When the annualized rate of BMD loss was compared by the
number of risk alleles, there was a significant association between
higher number of risk alleles and higher BMD loss (Figure 2). In
addition, the multiple-SNP models identified patients at the
highest risk of BMD loss. Patients carrying the highest number of
risk alleles had the most severe BMD loss.
Discussion
Our analysis identified a number of SNPs in bone metabolism
pathways predictive for acute BMD loss following HCT. Because
our candidate genes and SNPs have been previously implicated in
age-related bone loss, osteoporosis and/or bone phenotypes in the
general population, our findings support the hypothesis that HCT-
related BMD loss is an acceleration of the normal bone aging
process. Moreover, SNPs showed greater effects in HCT patients in
our study than those identified in the general population for bone
phenotypes. Four SNPs accounted for 35% of variance in femoral
BMD changeafter autologousHCT,whereasthe 12 mostsignificant
loci in a GWA study accounted for only about 3% of variance in hip
and spine BMD ina healthy Icelandic population [13]. The stronger
effect may be driven by potent exposures during HCT.
Among the 16 SNPs significant in our analysis, only rs9594738
in RANKL gene was related to BMD loss at both the spine and the
femur in allogeneic patients. This marginal overlap could be
attributed to differences in exposures related to allogeneic versus
autologous transplant procedures, as well as to differences in
susceptibility to HCT-induced BMD loss at these two anatomic
sites. The trabecular interconnection of the lumbar spine is much
higher than that of the femur [25]. Thus, the difference in bone
microarchitecture may explain the lack of overlap of SNPs
associated with BMD and risk of fracture at the two sites in
previous studies in the general populations [10] and the
observations that femoral bone was more susceptible to HCT-
induced bone loss than spinal bone [6,26].
A limitation of our study comes from the relatively small sample
size and the large number of tests performed: 122 SNPs in relation
to 4 quantitative outcomes in 121 patients stratified by autologous
and allogeneic HCT. The statistical power was thus limited.
Instead of using a Bonferroni correction, which would be over
conservative, we propose a hierarchy of evidence in our findings
based on curated knowledge of the SNPs in the literature.
The first level of evidence includes three SNPs implicated in two
GWA studies of bone phenotypes. We found that rs2075555 in the
intronic region of COL1A1 is associated with femoral BMD loss after
allogeneic HCT. The gene encodes for type I collagen, a major
matrix protein for bone formation and this SNP has been previously
associatedwithfemoralneckwidthinwomenandshaftwidthinmen
[11]. Two other SNPs, rs9594738 near RANKL and rs4870044 near
ESR1 from a GWA study of BMD in an Icelandic population [13],
and a meta-analysis of GWA studies of BMD
14,w e r ea l s os i g n i f i c a n t
in our study. RANKL plays a central role in coupling the activities of
osteoblasts and osteoclasts; and ESR1 encodes for estrogen receptor
alpha, which is key in estrogen-regulated activities.
The second level of evidence includes 9 SNPs, which have been
previously studied in relation to various bone phenotypes using a
candidate gene approach: rs4588 in GC, rs6256 in PTH, rs419598
in IL1RN, rs1801131 in MTHFR, rs1800896 in IL10, and
rs1061624 in TNFRSF1B, and rs1042358 in ALOX12, rs759330
in BGLAP, and rs2235579 in CLCN7 (Table S2). The first 5 SNPs
are among the most widely studied candidates for osteoporosis
and/or other bone phenotypes.
Figure 1. Annualized rate of bone mineral density change after hematopoietic cell transplantation by genotype for SNPs significant
in the multivariable models including clinical risk factors. Mean and standard error of the annualized rate of BMD change is plotted by
genotype for significant SNPs in the multivariable models including clinical risk factors. If the frequency of the homozygous variant genotype was
#5%, it was combined with the heterozygous genotype (includes rs3787557 [CYP24A1], rs6265 [PTH], rs1801131 [MTHFR] and rs2075555 [COL1A1]).
Please refer to Table S2 for a description of functions of these genes and SNPs. Abbreviation: BMD, bone mineral density; HCT, hematopoietic cell
transplantation; SNP, single nucleotide polymorphism.
doi:10.1371/journal.pone.0025940.g001
Table 3. Multiple SNP models of bone mineral density change after hematopoietic cell transplantation.
Outcome
Base model of
clinical factors Adjusted R
2 SNP (Gene) Adjusted R
2 DR
2
Spinal BMD change
after autologous HCT
Spinal BMD at baseline;
lymphoma vs others
0.10 rs759330 (BGALP); rs4588 (GC);
rs3787557 (CYP24A1)
0.26 0.16
Femoral BMD change
after autologous HCT
Age at HCT; lymphoma
vs others
0.12 rs419598 (IL1RN); rs1801131(MTHFR);
rs1042357 (ALOX12); rs4870044 (ESR1)
0.46 0.35
Spinal BMD change
after allogeneic HCT
Weight at HCT; spinal
BMD at baseline;
cortico-steroid dose
0.35 rs9594738 (RANKL) 0.40 0.05
Femoral BMD change
after allogeneic HCT
Weight at HCT; femoral
BMD at baseline;
cortico-steroid dose
0.14 rs9594738 (RANKL); rs1061624
(TNFRSF1B); rs2075555(COL1A1);
rs1321080 (RUNX2)
0.45 0.29
Footnote: R
2, coefficient of determination, provides an estimate of the proportion of BMD change that can be accounted for by all covariates in the model. DR
2 denotes
the increase in model accountability by adding SNP(s) to the base clinical risk factor model. All R
2 are adjusted by the number of covariates in the model. A higher DR
2
suggests an important role of genetics in addition to clinical risk factors for HCT-inducted BMD loss. Please refer to Table S2 for a description of the functions of these
genes and SNPs. Abbreviation: BMD, bone mineral density; HCT, hematopoietic cell transplantation; SNP, single nucleotide polymorphism.
single nucleotide polymorphism.
doi:10.1371/journal.pone.0025940.t003
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been previously studied in relation to bone phenotypes: rs3787557
and rs2296241 in CYP24A1, rs25645 in CSF3, and rs1321080 in
RUNX2. These SNPs are either tagSNPs or located in potentially
functional regions, and these genes were selected for their
importance in bone metabolism (Table S2).
As discussed above, we relied on a priori knowledge to rank our
confidence in our results: those previously implicated in GWA
studies were deemed most reliable, followed by those implicated in
candidate gene studies, and lastly those without support from the
literature. Although this knowledge-based hierarchy of evidence is
not statistically stringent, and we cannot exclude the possibility of
false positive (or negative) findings in our results, it aligns with our
exploratory purpose and provides support that genetic variants
contribute to post-HCT bone loss. Moreover, our findings may
provide clues for future studies. Thus, in addition to rs2075555 in
COL1A1, which remained significant in our analysis under the
most stringent threshold of significance, we also reported other
SNPs that may be interesting. Our study was designed to evaluate
only one post-HCT BMD measurement (about +100 days); thus
we do not know how the genetic variants described in our study
affect long-term BMD post-HCT. We chose day +100 for post-
HCT BMD measurement for three reasons. First, BMD loss
occurs at the highest rate within the first 3–6 months after HCT
[3], thus a true gene-exposure influence would be strongest in the
time period closest to the exposure. Second, patients who were
osteoporotic at their day +100 DXA scan were treated with a
bisphosphonate soon afterwards which may distort the association
between genotypes and BMD loss. Third, as an exploratory study,
BMD loss at day +100 was an outcome immediately available,
while we continue to follow-up patients with the plan to assess
genotypes and long-term BMD loss.
It is of interest to investigate the association of donor genotype
with BMD loss in allogeneic HCT recipients, considering their
hematopoietic cells, and thus osteoclast precursors, are replaced by
donors’ hematopoietic cells once complete donor chimerism has
been achieved. Unfortunately, donor DNA is not available from
the allogeneic HCT patients in this study. However, given that the
acute BMD loss we observed occurred quickly following
transplantation, prior to complete donor chimerism, and that
the acute BMD loss in our study was similar between autologous
and allogeneic HCT recipients (ie., in the absence and presence of
donor genomes), any effect of donor genotype may only be
evidenced in chronic BMD loss with longer follow-up. This
question warrants further investigation.
In summary, given the continuous bone loss due to normal
aging, accelerated post-HCT bone loss may never recover without
aggressive therapy, and HCT patients may be at much higher risk
of fracture compared to their age-matched peers. Considering the
well established relationship between low BMD and fracture risk
in the general population, we support the routine post HCT
surveillance guidelines developed by McClune et al [17]. Further
studies are needed to determine the impact and timing of different
prevention and/or intervention strategies.
Supporting Information
Figure S1 Log-transformed p-values for associations between
bone mineral density change and individual SNPs without
adjustment for clinical risk factors. Individual SNP (gene) remained
significant in the multivariable models including clinical risk factors
are labeled in circles. A number of other SNPs significant in
univariateanalysisbutdropped out ofmultivariateanalysiswerenot
labeled. Please refer to Table S2 for description of functions of these
genes and SNPs. Abbreviation: HCT, hematopoietic cell transplan-
tation; SNP, single nucleotide polymorphism.
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Table S1 Selected 122 single nucleotide polymorphisms from 46
candidate genes in bone metabolism pathways.
1SNPs that have
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Markers for Osteoporosis (GENOMOS) Consortium were labeled
as ‘‘GENOMOS SNPs’’. SNPs that have been identified in
genome wide association (GWA) studies were labeled as ‘‘GWAS
SNP’’. TagSNPs selected to represent genetic variations in genes
that have not been previous studied and have no common SNPs in
functional regions were labeled as ‘‘tagSNP’’. Functional regions
include 39 and 59 untranslated region (UTR) and codon. For
coding SNPs, amino acid changes are shown.
(DOC)
Table S2 Functions and summary of the published literature for
genes and SNPs significant in the individual SNP models including
clinical risk factors
(DOC)
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